Lacerta Therapeutics
Alachua
About Lacerta Therapeutics
Lacerta Therapeutics is a clinical stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system and lysosomal storage diseases. With unmatched scientific expertise and depth in the development, production, and application of AAV vectors, Lacerta Therapeutics is advancing its clinical programs using its proprietary capsid variants and scalable vector manufacturing platform. The experience and accomplishments of the Lacerta Therapeutics founders are unsurpassed in AAV gene therapy. In addition to world-class basic AAV vector development and gene therapy clinical trial expertise, our team brings to bear individuals with novel insight into developing novel, targeted neurological and lysosomal storage disease treatments.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $30.0M
- Last round: Series Unknown (Aug 2018)
- Website: lacertatherapeutics.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Genetics, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/lacerta-therapeutics-148324 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.